PCDHGA8: A Potential Drug Target and Biomarker (G9708)

Target Name: PCDHGA8

NCBI ID: G9708

PCDHGA8

PCDHGA8: A Potential Drug Target and Biomarker

PCDH-gamma-A8 (Peripheral Component Data Gamma-A8) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to investigate, and its functions have been extensively studied.

PCDH-gamma-A8 is a part of the Peripheral Component Data (PCD) family, which is a group of non-coding RNAs that play a crucial role in the development and maintenance of tissues and organs. The PCD family consists of several subfamilies, including PCDH1, PCDH2, PCDH3, and PCDH4. PCDH-gamma-A8 belongs to the PCDH3 subfamily.

PCDH-gamma-A8 is a small molecule RNA that is expressed in various tissues and organs, including the brain, heart, lungs, kidneys, and intestines. Its expression pattern varies depending on the tissue and developmental stage. PCDH-gamma-A8 is highly expressed in the human placenta, and its levels are decreasing with the aging process.

The functions of PCDH-gamma-A8 have been extensively studied, and its potential as a drug target and biomarker have been proposed. PCDH-gamma-A8 has been shown to play a role in various biological processes, including cell growth, apoptosis, and inflammation.

PCDH-gamma-A8 has been shown to promote cell growth by increasing the expression of genes involved in cell growth and division. It has also been shown to play a role in apoptosis by regulating the expression of genes involved in cell death. In addition, PCDH-gamma-A8 has been shown to regulate inflammation by modulating the expression of genes involved in inflammation.

PCDH-gamma-A8 has also been shown to be a potential biomarker for various diseases, including cancer. Its expression patterns have been found to be altered in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that PCDH-gamma-A8 has been associated with the development of certain diseases, such as neurodegenerative diseases and autoimmune diseases.

Due to its unique structure and functions, PCDH-gamma-A8 has potential as a drug target and biomarker. Studies have shown that blocking PCDH-gamma-A8 can lead to therapeutic effects in various diseases, including cancer. For example, studies have shown that inhibiting PCDH-gamma-A8 can lead to a reduction in the growth of cancer cells and a decrease in their migration.

In addition, PCDH-gamma-A8 has also been shown to be a potential biomarker for various diseases, including cancer. Its expression patterns have been found to be altered in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that PCDH-gamma-A8 has been associated with the development of certain diseases, such as neurodegenerative diseases and autoimmune diseases.

Overall, PCDH-gamma-A8 is a non-coding RNA molecule that has potential as a drug target and biomarker for various diseases. Further studies are needed to fully understand its functions and its potential as a therapeutic agent.

Protein Name: Protocadherin Gamma Subfamily A, 8

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHGA8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHGA8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets